Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 24 of 26, showing 5 Applications out of 128 total, starting on record 116, ending on 120

# Protocol No Study Title Investigator(s) & Site(s)

116.

ECCT/25/03/03   ALIM STUDY
    Evaluating the safety and efficacy of Imatinib in combination with Artemether and Lumefantrine for the treatment of Uncomplicated Malaria: a three-part trial.   
Principal Investigator(s)
1. Dr. QUENTIN AWORI
Site(s) in Kenya
VICTORIA BIOMEDICAL RESEARCH INSTITUTE
 
View

117.

ECCT/19/12/01   BOHEMIA PK400
    Mosquitocidal effect and pharmacokinetics of different ivermectin dose regimens in preparation for BOHEMIA cluster randomized controlled trial.   
Principal Investigator(s)
1. Marta Ferreira Maia
Site(s) in Kenya
Kilifi
 
View

118.

ECCT/22/01/02   CoVPN 3008
    Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern   
Principal Investigator(s)
1. Ben Madeke Andagalu
Site(s) in Kenya
1. KEMRI -USAMRD-A, Kombewa Clinical Research Centre (Kisumu county)
2. KEMRI-CGHR (Kisumu county)
 
View

119.

ECCT/16/07/05   HESTIA 1
    Multicentre, open-label, randomised, pharmacokinetic (PK) and pharmacodynamic (PD) dose-ranging Phase II study of ticagrelor followed by a double-blind, randomised, parallel-group, placebo-controlled 4 weeks extension phase in paediatric patients with sickle cell disease   
Principal Investigator(s)
1. Jessie Nyokabi Githanga
2. Videlis Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. Gertrude’s Children’s Hospital (Nairobi City county)
2. Kemri CRDR research center at Chandaria Health Centre Dagoretti (Nairobi City county)
3. Clinical Research Annex at the Siaya County Referral Hospital (Siaya county)
4. Kondele Children’s Hospital, KEMRI – Centre for Clinical Research (Kisumu county)
 
View

120.

ECCT/23/10/05   CAPTURE-2
    Phase 2a Proof-of-Concept, Multicenter, Randomized, Open Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of the Combination M5717-pyronaridine as Chemoprevention in Asymptomatic Adults and Adolescents with Plasmodium falciparum Malaria Infection.   
Principal Investigator(s)
1. Dr Lucas Otieno Tina Otieno Tina
Site(s) in Kenya
Victoria Biomedical Research Institute
 
View